This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs. placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a period of 4 weeks in treatment of relief of upper GI symptoms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
808
To assess the efficacy of esomeprazole versus placebo through 4 weeks of treatment of upper GI symptoms associated with nonsteroidal anti-inflammation
- To assess the safety & tolerability of esomeprazole versus placebo when administered for up to 4 weeks to patients receiving daily NSAID therapy
- To assess the impact of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Tucson, Arizona, United States
Research Site
Anaheim, California, United States
Research Site
Orange, California, United States
Research Site
San Francisco, California, United States
Research Site
Bradenton, Florida, United States
Research Site
Clearwater, Florida, United States
Research Site
Fort Lauderdale, Florida, United States
Research Site
Jacksonville, Florida, United States
Research Site
South Miami, Florida, United States
Research Site
West Palm Beach, Florida, United States
...and 109 more locations